Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

E.J.J. Berm; E. Hak; M. Postma; M. Boshuisen; L. Breuning; J.R.B.J. Brouwers; T. Dhondt; P.A.F. Jansen; R.M. Kok; J.G. Maring; R.J. van Marum; H. Mulder; R.C.O. Voshaar; A.J. Risselada; H. Venema; L. Vleugel; B. Wilffert

doi:https://doi.org/10.1186/s13063-015-0561-0

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

E.J.J. Berm, E. Hak, M. Postma, M. Boshuisen, L. Breuning, J.R.B.J. Brouwers, T. Dhondt, P.A.F. Jansen, R.M. Kok, J.G. Maring, R.J. van Marum, H. Mulder, R.C.O. Voshaar, A.J. Risselada, H. Venema, L. Vleugel, B. Wilffert

General Practice (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

Original language	English
Pages (from-to)	37
Journal	Trials
Volume	16
DOIs	https://doi.org/10.1186/s13063-015-0561-0
Publication status	Published - 2015

Access to Document

https://doi.org/10.1186/s13063-015-0561-0

Cite this

Berm, E. J. J., Hak, E., Postma, M., Boshuisen, M., Breuning, L., Brouwers, J. R. B. J., Dhondt, T., Jansen, P. A. F., Kok, R. M., Maring, J. G., van Marum, R. J., Mulder, H., Voshaar, R. C. O., Risselada, A. J., Venema, H., Vleugel, L., & Wilffert, B. (2015). Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials, 16, 37. https://doi.org/10.1186/s13063-015-0561-0

@article{badcccc5f93d4dbfb438d9ccf27e3863,

title = "Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)",

author = "E.J.J. Berm and E. Hak and M. Postma and M. Boshuisen and L. Breuning and J.R.B.J. Brouwers and T. Dhondt and P.A.F. Jansen and R.M. Kok and J.G. Maring and {van Marum}, R.J. and H. Mulder and R.C.O. Voshaar and A.J. Risselada and H. Venema and L. Vleugel and B. Wilffert",

year = "2015",

doi = "https://doi.org/10.1186/s13063-015-0561-0",

language = "English",

volume = "16",

pages = "37",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central",

}

Berm, EJJ, Hak, E, Postma, M, Boshuisen, M, Breuning, L, Brouwers, JRBJ, Dhondt, T, Jansen, PAF, Kok, RM, Maring, JG, van Marum, RJ, Mulder, H, Voshaar, RCO, Risselada, AJ, Venema, H, Vleugel, L & Wilffert, B 2015, 'Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)', Trials, vol. 16, pp. 37. https://doi.org/10.1186/s13063-015-0561-0

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). / Berm, E.J.J.; Hak, E.; Postma, M. et al.
In: Trials, Vol. 16, 2015, p. 37.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

AU - Berm, E.J.J.

AU - Hak, E.

AU - Postma, M.

AU - Boshuisen, M.

AU - Breuning, L.

AU - Brouwers, J.R.B.J.

AU - Dhondt, T.

AU - Jansen, P.A.F.

AU - Kok, R.M.

AU - Maring, J.G.

AU - van Marum, R.J.

AU - Mulder, H.

AU - Voshaar, R.C.O.

AU - Risselada, A.J.

AU - Venema, H.

AU - Vleugel, L.

AU - Wilffert, B.

PY - 2015

Y1 - 2015

U2 - https://doi.org/10.1186/s13063-015-0561-0

DO - https://doi.org/10.1186/s13063-015-0561-0

M3 - Article

C2 - 25636328

SN - 1745-6215

VL - 16

SP - 37

JO - Trials

JF - Trials

ER -